Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients

Joon Mo Kim, Tae Woo Kim, Chan Yun Kim, Hwang Ki Kim, Ki Ho Park

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5 % timolol ophthalmic solution in normal-tension glaucoma (NTG) patients. Methods: This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients—55 undergoing therapy with BTFC and 55 0.5 %, with timolol—participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70 %. Ultimately, a total of 95 patients—48 in the BTFC group and 47 in the 0.5 % timolol group—completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators. Results: The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5 % timolol group. The ratio of patients whose average IOP had decreased by >20 % after 4 and 12 weeks was 50 and 56 % in the BTFC group, respectively, whereas it was 29.41 and 23.53 % in the 0.5 % timolol group, respectively (p = 0.034, <0.001). Conclusions: BTFC has a superior IOP-lowering effect than 0.5 % timolol in NTG patients.

Original languageEnglish
Pages (from-to)20-26
Number of pages7
JournalJapanese Journal of Ophthalmology
Volume60
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Low Tension Glaucoma
Timolol
Intraocular Pressure
Safety
Ophthalmic Solutions
Brimonidine Tartrate
Glaucoma
Compliance

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{d09226212035459a8b582dbf89b0a8de,
title = "Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 {\%} timolol in normal-tension glaucoma patients",
abstract = "Purpose: To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5 {\%} timolol ophthalmic solution in normal-tension glaucoma (NTG) patients. Methods: This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients—55 undergoing therapy with BTFC and 55 0.5 {\%}, with timolol—participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70 {\%}. Ultimately, a total of 95 patients—48 in the BTFC group and 47 in the 0.5 {\%} timolol group—completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators. Results: The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5 {\%} timolol group. The ratio of patients whose average IOP had decreased by >20 {\%} after 4 and 12 weeks was 50 and 56 {\%} in the BTFC group, respectively, whereas it was 29.41 and 23.53 {\%} in the 0.5 {\%} timolol group, respectively (p = 0.034, <0.001). Conclusions: BTFC has a superior IOP-lowering effect than 0.5 {\%} timolol in NTG patients.",
author = "Kim, {Joon Mo} and Kim, {Tae Woo} and Kim, {Chan Yun} and Kim, {Hwang Ki} and Park, {Ki Ho}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s10384-015-0420-2",
language = "English",
volume = "60",
pages = "20--26",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "1",

}

Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients. / Kim, Joon Mo; Kim, Tae Woo; Kim, Chan Yun; Kim, Hwang Ki; Park, Ki Ho.

In: Japanese Journal of Ophthalmology, Vol. 60, No. 1, 01.01.2016, p. 20-26.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients

AU - Kim, Joon Mo

AU - Kim, Tae Woo

AU - Kim, Chan Yun

AU - Kim, Hwang Ki

AU - Park, Ki Ho

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5 % timolol ophthalmic solution in normal-tension glaucoma (NTG) patients. Methods: This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients—55 undergoing therapy with BTFC and 55 0.5 %, with timolol—participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70 %. Ultimately, a total of 95 patients—48 in the BTFC group and 47 in the 0.5 % timolol group—completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators. Results: The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5 % timolol group. The ratio of patients whose average IOP had decreased by >20 % after 4 and 12 weeks was 50 and 56 % in the BTFC group, respectively, whereas it was 29.41 and 23.53 % in the 0.5 % timolol group, respectively (p = 0.034, <0.001). Conclusions: BTFC has a superior IOP-lowering effect than 0.5 % timolol in NTG patients.

AB - Purpose: To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5 % timolol ophthalmic solution in normal-tension glaucoma (NTG) patients. Methods: This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients—55 undergoing therapy with BTFC and 55 0.5 %, with timolol—participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70 %. Ultimately, a total of 95 patients—48 in the BTFC group and 47 in the 0.5 % timolol group—completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators. Results: The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5 % timolol group. The ratio of patients whose average IOP had decreased by >20 % after 4 and 12 weeks was 50 and 56 % in the BTFC group, respectively, whereas it was 29.41 and 23.53 % in the 0.5 % timolol group, respectively (p = 0.034, <0.001). Conclusions: BTFC has a superior IOP-lowering effect than 0.5 % timolol in NTG patients.

UR - http://www.scopus.com/inward/record.url?scp=84954398226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954398226&partnerID=8YFLogxK

U2 - 10.1007/s10384-015-0420-2

DO - 10.1007/s10384-015-0420-2

M3 - Article

C2 - 26578422

AN - SCOPUS:84954398226

VL - 60

SP - 20

EP - 26

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 1

ER -